跳至主要内容
临床试验/CTRI/2021/07/034579
CTRI/2021/07/034579尚未招募未知

Retrospective observational study to determine factors influencing outcome in patients with Human Epidermal Growth Factor Receptor 2 positive breast cancers who receive neoadjuvant chemotherapy

il0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.All individuals above 18 years of age with histologically confirmed HER2 positive breast cancers who received neoadjuvant chemotherapy during the period of January 2014 to December 2018.
  • 2.Patients who have received even 1 cycle of treatment in the neoadjuvant setting will be included in the analysis.
  • 3.Patients who have received one or more of the following treatments as part of neoadjuvant treatment will be included in the study: chemotherapy and/or HER2targeted therapy.
  • 4.Patients with Stage 1 to Stage 3 breast cancer (AJCC 7th edition 2010) will be included in the analysis

排除标准

  • 1.Individuals with HER2 positive breast cancers who did not receive neoadjuvant therapy for any reason
  • 2.Upfront metastatic HER2 positive breast cancers
  • 3.Individuals with other coexistent malignancies

研究者

发起方
il

相似试验

Observational research to study the factors that can... | 临床试验